Vyant Bio, Inc. (OTCMKTS:VYNT – Get Free Report)’s stock price rose 7.8% on Friday . The stock traded as high as $0.20 and last traded at $0.19. Approximately 19,100 shares traded hands during trading, a decline of 88% from the average daily volume of 161,822 shares. The stock had previously closed at $0.18.
Vyant Bio Stock Performance
The company’s 50 day moving average is $0.19 and its 200 day moving average is $0.19. The company has a debt-to-equity ratio of 0.04, a current ratio of 2.86 and a quick ratio of 2.86.
About Vyant Bio
Vyant Bio, Inc, a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD).
Recommended Stories
- Five stocks we like better than Vyant Bio
- CD Calculator: Certificate of Deposit Calculator
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- Business Services Stocks Investing
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- What is Put Option Volume?
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Vyant Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vyant Bio and related companies with MarketBeat.com's FREE daily email newsletter.
